333 related articles for article (PubMed ID: 28675638)
41. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
42. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
[TBL] [Abstract][Full Text] [Related]
43. [Treatment strategy for infants with acute lymphoblastic leukemia].
Miyamura T
Rinsho Ketsueki; 2019; 60(9):1317-1323. PubMed ID: 31597858
[TBL] [Abstract][Full Text] [Related]
44. Identification of co-expressed genes associated with MLL rearrangement in pediatric acute lymphoblastic leukemia.
Zhang H; Liu B; Cheng J; Ma H; Li Z; Xi Y
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32347296
[TBL] [Abstract][Full Text] [Related]
45. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
[TBL] [Abstract][Full Text] [Related]
46. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
Mata JF; Scrideli CA; Queiroz RP; Mori BO; Emerenciano M; Pombo-de-Oliveira MS; Tone LG
Braz J Med Biol Res; 2006 Nov; 39(11):1417-23. PubMed ID: 17146554
[TBL] [Abstract][Full Text] [Related]
47. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
48. Trametinib inhibits
Kerstjens M; Pinhancos SS; Castro PG; Schneider P; Wander P; Pieters R; Stam RW
Haematologica; 2018 Apr; 103(4):e147-e150. PubMed ID: 29419436
[No Abstract] [Full Text] [Related]
49. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
Stumpel DJ; Schotte D; Lange-Turenhout EA; Schneider P; Seslija L; de Menezes RX; Marquez VE; Pieters R; den Boer ML; Stam RW
Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
[TBL] [Abstract][Full Text] [Related]
50. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
51. B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
Kemps PG; Cleven AHG; van Wezel T; van Eijk R; Bot FJ; Veelken H; van Balen P; Kerkhoffs JH
Am J Hematol; 2020 Nov; 95(11):1427-1429. PubMed ID: 32243611
[No Abstract] [Full Text] [Related]
52. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
53. Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
Fechina L; Popov A; Tsaur G; Henze G; Shorikov E; Makarova O; Khlebnikova O; Zhukova Y; Arakaev O; Streneva O; Verzhbitskaya T; Riger T; Solodovnikov A; Lapotentova E; Aleinikova O; Myakova N; Boichenko E; Kondratchik K; Nikonova O; Shapochnik A; Goroshkova M; Ponomareva N; Novichkova G; Karachunskiy A; Roumiantsev A
Leukemia; 2023 Nov; 37(11):2276-2281. PubMed ID: 37741948
[No Abstract] [Full Text] [Related]
54. Unusual profiles of pediatric acute lymphoblastic leukemia with MLL gene rearrangement.
Kubicka M; Soszynska K; Mucha B; Rafinska B; Kolodziej B; Haus O; Styczynski J
Leuk Lymphoma; 2007 Oct; 48(10):2083-6. PubMed ID: 17917979
[No Abstract] [Full Text] [Related]
55. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
[TBL] [Abstract][Full Text] [Related]
56. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
57. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.
Agraz-Doblas A; Bueno C; Bashford-Rogers R; Roy A; Schneider P; Bardini M; Ballerini P; Cazzaniga G; Moreno T; Revilla C; Gut M; Valsecchi MG; Roberts I; Pieters R; De Lorenzo P; Varela I; Menendez P; Stam RW
Haematologica; 2019 Jun; 104(6):1176-1188. PubMed ID: 30679323
[TBL] [Abstract][Full Text] [Related]
58. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
[TBL] [Abstract][Full Text] [Related]
59. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.
Andersson AK; Ma J; Wang J; Chen X; Gedman AL; Dang J; Nakitandwe J; Holmfeldt L; Parker M; Easton J; Huether R; Kriwacki R; Rusch M; Wu G; Li Y; Mulder H; Raimondi S; Pounds S; Kang G; Shi L; Becksfort J; Gupta P; Payne-Turner D; Vadodaria B; Boggs K; Yergeau D; Manne J; Song G; Edmonson M; Nagahawatte P; Wei L; Cheng C; Pei D; Sutton R; Venn NC; Chetcuti A; Rush A; Catchpoole D; Heldrup J; Fioretos T; Lu C; Ding L; Pui CH; Shurtleff S; Mullighan CG; Mardis ER; Wilson RK; Gruber TA; Zhang J; Downing JR;
Nat Genet; 2015 Apr; 47(4):330-7. PubMed ID: 25730765
[TBL] [Abstract][Full Text] [Related]
60. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Zoghbi A; Zur Stadt U; Winkler B; Müller I; Escherich G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
